Cargando…

A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy

Objective: To evaluate the hemostasis and coagulation effect of Hemocoagulase Bothrops Atrox in benign prostatic hyperplasia (BPH) patients undergoing transurethral bipolar plasmakinetic prostatectomy (TUPKP). Methods: This study adopted a multicenter, prospective, and real world design. BPH patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bing-Hui, Yu, Zhao-Jun, Wang, Chao-Yang, Zi, Hao, Li, Xiao-Dong, Wang, Xing-Huan, Ren, Xuan-Yi, Liu, Tong-Zu, Zheng, Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890842/
https://www.ncbi.nlm.nih.gov/pubmed/31827440
http://dx.doi.org/10.3389/fphar.2019.01426
_version_ 1783475700113604608
author Li, Bing-Hui
Yu, Zhao-Jun
Wang, Chao-Yang
Zi, Hao
Li, Xiao-Dong
Wang, Xing-Huan
Ren, Xuan-Yi
Liu, Tong-Zu
Zheng, Hang
author_facet Li, Bing-Hui
Yu, Zhao-Jun
Wang, Chao-Yang
Zi, Hao
Li, Xiao-Dong
Wang, Xing-Huan
Ren, Xuan-Yi
Liu, Tong-Zu
Zheng, Hang
author_sort Li, Bing-Hui
collection PubMed
description Objective: To evaluate the hemostasis and coagulation effect of Hemocoagulase Bothrops Atrox in benign prostatic hyperplasia (BPH) patients undergoing transurethral bipolar plasmakinetic prostatectomy (TUPKP). Methods: This study adopted a multicenter, prospective, and real world design. BPH patients undergoing TUPKP were divided into two groups according to whether they adopted Hemocoagulase Bothrops Atrox (group B) or not (group A) during perioperative period. The electronic clinical data on every included subject, including the international prostate symptom score (IPSS) and the quality of life scale (QoL), maximum urinary flow rate (Qmax), complete blood count, coagulation screening test and adverse events, were measured and compared between the two groups. Results: Finally, 695 patients, 443 in group A and 252 in group B were included. Baseline characteristics showed no significant difference between two groups. In group A, compared with baseline, IPSS decreased 15.66 (95% CI = −16.45 to −14.87), QoL decreased 3.08 (95% CI = −3.30 to −2.87), prothrombin time prolonged 1.02 s (95% CI = 0.56 to 1.48), while white blood cells, neutrophils, lymphocytes, and hemoglobin also significantly changed; white blood cells, neutrophils and platelets increased, while lymphocytes decreased by 0.14×109/L (95% CI = −0.21 to −0.08) before discharge. In group B, compared with baseline, IPSS decreased 16.12 (95% CI = −17.02 to −15.21), QoL decreased 3.32 (95% CI = −3.56 to −3.07), and white blood cells, neutrophils, lymphocytes, and hemoglobin were also significantly changed, along with white blood cells and lymphocytes that tested before discharge (p < 0.01); however, prothrombin time was not significant prolonged (MD= 0.48, 95% CI = −0.05 to 1.01). When compared with group A and group B, the average hospitalization time in group A was longer than group B (p < 0.01), transfusion risk was similar in the two groups (OR = 1.582, 95% CI = 0.552 to 4.538). Parameters had no substantial difference between the two subgroups whether prostate volume was more than 80 mL or not. Conclusion: Our study indicated that Hemocoagulase Bothrops Atrox can shorten the prothrombin time, hospitalization time and is probably safe among BPH patients undergoing TUPKP, exhibiting fine hemostasis and coagulation efficacy, and would not be influenced by prostate volume.
format Online
Article
Text
id pubmed-6890842
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68908422019-12-11 A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy Li, Bing-Hui Yu, Zhao-Jun Wang, Chao-Yang Zi, Hao Li, Xiao-Dong Wang, Xing-Huan Ren, Xuan-Yi Liu, Tong-Zu Zheng, Hang Front Pharmacol Pharmacology Objective: To evaluate the hemostasis and coagulation effect of Hemocoagulase Bothrops Atrox in benign prostatic hyperplasia (BPH) patients undergoing transurethral bipolar plasmakinetic prostatectomy (TUPKP). Methods: This study adopted a multicenter, prospective, and real world design. BPH patients undergoing TUPKP were divided into two groups according to whether they adopted Hemocoagulase Bothrops Atrox (group B) or not (group A) during perioperative period. The electronic clinical data on every included subject, including the international prostate symptom score (IPSS) and the quality of life scale (QoL), maximum urinary flow rate (Qmax), complete blood count, coagulation screening test and adverse events, were measured and compared between the two groups. Results: Finally, 695 patients, 443 in group A and 252 in group B were included. Baseline characteristics showed no significant difference between two groups. In group A, compared with baseline, IPSS decreased 15.66 (95% CI = −16.45 to −14.87), QoL decreased 3.08 (95% CI = −3.30 to −2.87), prothrombin time prolonged 1.02 s (95% CI = 0.56 to 1.48), while white blood cells, neutrophils, lymphocytes, and hemoglobin also significantly changed; white blood cells, neutrophils and platelets increased, while lymphocytes decreased by 0.14×109/L (95% CI = −0.21 to −0.08) before discharge. In group B, compared with baseline, IPSS decreased 16.12 (95% CI = −17.02 to −15.21), QoL decreased 3.32 (95% CI = −3.56 to −3.07), and white blood cells, neutrophils, lymphocytes, and hemoglobin were also significantly changed, along with white blood cells and lymphocytes that tested before discharge (p < 0.01); however, prothrombin time was not significant prolonged (MD= 0.48, 95% CI = −0.05 to 1.01). When compared with group A and group B, the average hospitalization time in group A was longer than group B (p < 0.01), transfusion risk was similar in the two groups (OR = 1.582, 95% CI = 0.552 to 4.538). Parameters had no substantial difference between the two subgroups whether prostate volume was more than 80 mL or not. Conclusion: Our study indicated that Hemocoagulase Bothrops Atrox can shorten the prothrombin time, hospitalization time and is probably safe among BPH patients undergoing TUPKP, exhibiting fine hemostasis and coagulation efficacy, and would not be influenced by prostate volume. Frontiers Media S.A. 2019-11-27 /pmc/articles/PMC6890842/ /pubmed/31827440 http://dx.doi.org/10.3389/fphar.2019.01426 Text en Copyright © 2019 Li, Yu, Wang, Zi, Li, Wang, Ren, Liu and Zheng http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Bing-Hui
Yu, Zhao-Jun
Wang, Chao-Yang
Zi, Hao
Li, Xiao-Dong
Wang, Xing-Huan
Ren, Xuan-Yi
Liu, Tong-Zu
Zheng, Hang
A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title_full A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title_fullStr A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title_full_unstemmed A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title_short A Preliminary, Multicenter, Prospective and Real World Study on the Hemostasis, Coagulation, and Safety of Hemocoagulase Bothrops Atrox in Patients Undergoing Transurethral Bipolar Plasmakinetic Prostatectomy
title_sort preliminary, multicenter, prospective and real world study on the hemostasis, coagulation, and safety of hemocoagulase bothrops atrox in patients undergoing transurethral bipolar plasmakinetic prostatectomy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890842/
https://www.ncbi.nlm.nih.gov/pubmed/31827440
http://dx.doi.org/10.3389/fphar.2019.01426
work_keys_str_mv AT libinghui apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT yuzhaojun apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT wangchaoyang apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT zihao apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT lixiaodong apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT wangxinghuan apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT renxuanyi apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT liutongzu apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT zhenghang apreliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT libinghui preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT yuzhaojun preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT wangchaoyang preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT zihao preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT lixiaodong preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT wangxinghuan preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT renxuanyi preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT liutongzu preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy
AT zhenghang preliminarymulticenterprospectiveandrealworldstudyonthehemostasiscoagulationandsafetyofhemocoagulasebothropsatroxinpatientsundergoingtransurethralbipolarplasmakineticprostatectomy